Dr Stephanie Fowler (UCL Queen Square Institute of Neurology) highlighted that treatments called antisense oligonucleotides are in development that reduce cells’ manufacturing of tau which play a key role in Alzheimer’s disease pathophysiology.
Read: New Scientist (£)
Close
